Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEPLISAV in Adults With End-Stage Renal Disease
NCT00498212Phase 2Terminated
- Sponsor
- Dynavax Technologies
- Start
- Jul 2007
- Primary completion
- Aug 2008
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Heplisav-B in hepatitis B (HBV) (2 arms), sponsored by Dynavax Technologies. Primary endpoint: Occurrence of adverse events and local and systemic reaction rates at 28 weeks. Started Jul 2007; status: terminated.
02
Drugs
Heplisav-B
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT00498212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00498212.